

H-11

7-20-01

0300

0420

Docket No: AHP 98126 P2  
Patent

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Ozenberger, et al.  
Serial No.: 09/852,100 Group Art No.: TBD  
Filed: May 9, 2001 Examiner: TBD  
For: Beta-Amyloid Peptide-Binding Proteins and Polynucleotides Encoding  
the Same  
Confirmation No.: TBD  
Customer Number: 25291

Commissioner for Patents  
Box DD  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

**CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL564797277US addressed to the Commissioner for Patents, Box DD, Washington, DC 20231.

July 19, 2001  
Date

Julia Richie  
Julia Richie

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☒ is filed within three months of the filing date of the application.
- b. ☐ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e)  
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☐ Newly Cited Information  
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed.

☒ Previously Cited Information  
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.  
Prior application is Serial Number 09/774,936, filed on January 31, 2001 of Bradley A. Ozenberger, Jonathan A. Bard, Eileen M. Kajkowski, Jack S. Jacobsen, Stephen G. Walker, Heidi Sofia, & David Howland for Beta-Amyloid Peptide-Binding Proteins and Polynucleotides Encoding the Same.


- ☐ Concise Explanation  
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
- ☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:  
Charge Deposit Account No. 01-1425 in the amount of \$0.00  
A duplicate of this statement is enclosed.


Instructions as to Overpayment/Underpayment:  
Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.

  
\_\_\_\_\_  
Gavin T. Bogle

See Attached Certificate

American Home Products Corporation  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940-0874  
Tel. No. (617) 665-8079

<b>LIST OF PATENT AND PUBLICATION FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (USE SEVERAL SHEETS IF NECESSARY)	<b>Docket No.:</b> AHP 98126 P2	<b>Application No.:</b> 09/852,100
	<b>Applicant(s):</b> B.A. Ozenberger et al.	
	<b>Filing Date:</b> May 9, 2001	<b>Group Art Unit:</b>



### US PATENT DOCUMENTS

Examiner Initial		Doc. No.	Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

### FOREIGN PATENT DOCUMENTS

Examiner Initial		Doc. No.	Date	Country	Class	Sub-Class	Translation Yes No	
	AL	WO 96/25435	22 Aug 96	PCT				
	AM	WO 88/03951	2 Jun 88	PCT				
	AN	WO 96/13513	9 May 96	PCT				
	AO	WO 98/46636	22 Oct 98	PCT				
	AP	WO 99/46289	16 Sep 99	PCT				
	AQ	WO 99/24836	20 May 99	PCT				
	AL2	WO 00/22125	20 Apr 00	PCT				

### OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

1.	AR	J. Biol. Chem., "Modulation of GDP Release from Transducin by the Conserved Glu <sup>134</sup> Arg <sup>135</sup> Sequence in Rhodopsin", S. Acharya et al., <u>271</u> , No. 41, (Oct. 1996) pp. 25406-411;
2.	AS	J. Mol. Biol., "Basic Local Alignment Search Tool", S.F. Altschul et al., (1990) <u>215</u> , pp. 403-410;
3.	AT	Lett. Nature, "Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor", F. Revah et al., <u>353</u> , (Oct. 1991), pp. 846- ;

OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)


4.	<b>AU</b>	Nature, "RAGE and Amyloid- $\beta$ -peptide neurotoxicity in Alzheimer's disease", Shi Du Yan et al., <u>382</u> , (Aug. 1996) pp. 685-691;
5.	<b>AV</b>	Nature, "Scavenger receptor-mediated adhesion of microglia to $\beta$ -amyloid fibrils", J. El Khoury et al., <u>382</u> (Aug. 1996), pp. 716-719;
6.	<b>AW</b>	Nature, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease", <u>349</u> (Feb. 1991), pp. 704-706;
7.	<b>AX</b>	Nature Genetics, "Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the $\beta$ -amyloid precursor protein gene", L. Hendriks et al., <u>1</u> (June 1992), pp. 218-221.
8.	<b>AY</b>	Neurobiology of Aging, "A novel species-specific RNA related to alternatively spliced amyloid precursor protein mRNAs", J.S. Jacobsen et al., <u>12</u> , (1991) pp. 575-583.
9.	<b>AZ</b>	J. Biol. Chem., "The release of Alzheimer's disease $\beta$ amyloid peptide is reduced by phorbol treatment", J.S. Jacobsen et al., <u>269</u> , No. 11 (March 1994), pp. 8376-8382.
10.	<b>AR2</b>	Mol. Cell. Biol., "Effects of expression of mammalian G $\alpha$ and hybrid mammalian yeast G $\alpha$ proteins on the yeast pheromone response signal transduction pathway", Yoon-Se Kang et al., <u>10</u> , No. 6 (June 1990), pp. 2582-2590.
11.	<b>AS2</b>	Nat. Genetics, "The Alzheimer's A $\beta$ peptide induces neurodegeneration and apoptotic cell death in transgenic mice", <u>9</u> , (Jan. 1995), pp.21-30.
12.	<b>AT2</b>	A. Neuropathol., "Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ", H. Lassman et al., <u>89</u> (Springer-Verlag 1995), pp. 35-41.
13.	<b>AU2</b>	Science, "Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type", <u>243</u> , (June 1990), pp. 1124-1126.
14.	<b>AV2</b>	Proc. Natl. Acad. Sci., "Apoptosis is induced by $\beta$ -amyloid in cultured central nervous system neurons", D.T. Loo et al., <u>90</u> , (Sept. 1993), pp. 7951-7955.
15.	<b>AW2</b>	Proc. Natl. Acad. Sci., "Reversible in vitro growth of Alzheimer disease $\beta$ -amyloid plaques by deposition of labeled amyloid peptide", J.E. Maggio et al., <u>89</u> (June 1992), pp. 5462-5466.
16.	<b>AX2</b>	Nat. Genetics, "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of $\beta$ -amyloid", M. Mullan et al., <u>1</u> (Aug. 1992), pp. 345-347.

**OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)**

17.	<b>AY2</b>	Sci., "A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease", J. Murrell et al., <u>254</u> (Oct. 1991), pp. 97-99.
18.	<b>AZ2</b>	Lett. Nat., "Alzheimer amyloid protein precursor complements with brain GTP-binding protein G <sub>o</sub> ", I. Nishimoto et al., <u>362</u> (March 1993), pp. 75-79.
19.	<b>AR3</b>	Nature Medicine, "Secreted amyloid $\beta$ -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease", D. Scheuner et al., <u>2</u> No. 8 (Aug. 1996), pp. 864-70.
20.	<b>AS3</b>	Science, "Alzheimer's Disease: Genotypes, Phenotype, and Treatments", D.J. Selkoe, <u>275</u> (Jan. 1997), pp. 630-31.
21.	<b>AT3</b>	J. Neurosci., "Voltage-gated K <sup>+</sup> channel $\beta$ subunits: Expression and distribution of Kv $\beta$ 1 and Kv $\beta$ 2 in adult rat brain", K.J. Rhodes et al., <u>16</u> (Aug. 1996), pp. 4846-60.
22.	<b>AU3</b>	Mol. Endo., "Functional interaction of ligands and receptors of the hematopoietic superfamily in yeast", B.A. Ozenberger et al., <u>9</u> No. 10 (1995), pp. 1321-29.
23.	<b>AV3</b>	Exp. Neurology, "Evidence of apoptotic cell death in Alzheimer's disease", G. Smale et al., <u>133</u> (1995), pp. 225-30.
24.	<b>AW3</b>	Sci., "Amyloid $\beta$ protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus", (Jan. 1987), pp. 880-84.
25.	<b>AX3</b>	Proc. Natl. Acad. Sci., "Detection of conserved segments in proteins: Iterative scanning of sequence databases with alignment blocks", R.L. Tatusov et al., <u>91</u> (Dec. 1994), pp. 12091-95.
26.	<b>AY3</b>	Cell, "The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases", J. Wade Harper et al., <u>75</u> (Nov. 1993), pp. 805-16.
27.	<b>AZ3</b>	Elsevier Sci., "Ultrastructural analysis of $\beta$ -amyloid-induced apoptosis in cultured hippocampal neurons", J.A. Watt et al., <u>661</u> (1994), pp. 147-156.
28.	<b>AR4</b>	Sci., "G-protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP", T. Yamatsuji et al., <u>272</u> (May 1996), pp. 1349-52.
29.	<b>AS4</b>	Nature, "An intracellular protein that binds amyloid- $\beta$ peptide and mediates neurotoxicity in Alzheimer's disease", Shi Du Yan et al., <u>389</u> (Oct. 1997), pp. 689-

**OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)**

30.	<b>AT4</b>	Science, Lewin, <u>237</u> (1987), p. 1570.
31.	<b>AU4</b>	Biotech Adv., Gellissen et al., <u>10</u> (1992), pp. 179-189
32.	<b>AV4</b>	Nature, Adams et al., <u>377</u> (1995), pp. 3-174.
33.	<b>AW4</b>	Genbank Accession Number AA306979, Adams et al., 1995.
34.	<b>AX4</b>	Glossary of Genetics and Cytogenetics, Rieger et al., 1976, pp. 17-18.
35.	<b>AY4</b>	Journal of Cell Biology, Burgess et al., <u>111</u> (1990), pp. 2129-2138.
36.	<b>AZ4</b>	Molecular and Cellular Biology, Lazar et al., <u>8(3)</u> (March 1988), pp. 1247-1252.
37.	<b>AR5</b>	"Peptide Hormones," Rudinger, University Park Press, June 1976, pp. 1-7.
38.	<b>AS5</b>	"Molecular Cloning," Sambrook et al., Second Edition, Cold Spring Harbor Laboratory Press, 1989, pp. 17.1-17.44.
39.	<b>AT5</b>	DATABASE EMBL - EMBEST7 'Online! Entry/Acc.no. AI143226, 29 September 1998 (1998-09-29) Strausberg, R., "qb76e01.x1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:1706040 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN; mRNA sequence." XP002135394
40.	<b>AU5</b>	DATABASE EMBL - EMBEST1 'Online! Entry/Acc.no. AA628537, 28 October 1997 (1997-10-28) Hillier, L., et al., "af27h04.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032919 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN;." XP002135395
41.	<b>AV5</b>	DATABASE EMBL - EMBEST3 'Online! Entry/Acc.no. AA772225, 31 January 31, 1998 (1998-01-31) Strausberg, R., et al., "ai41c01.s1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone 1359552 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN; mRNA" XP002135396
42.	<b>AW5</b>	Proc. Nat'l. Acad. Sci. USA, "Expression, stability, and membrane integration of truncation mutants of bovine rhodopsin," Heymann, J.A.W., et al., <u>94</u> (1997), pp. 4966-4971.



claim a G protein coupled

JUL 19 2001

ES 10 May 1998 X  
as muscle cDNA c

claim a G protein coupled

JUL 19 2001

ES 10 May 1998 X  
as muscle cDNA c